- Abdominal Obesity, Metabolic Syndrome, and Risk of Cardiovascular Disease
- Abdominal Obesity in Type 2 Diabetes
- Obesity and Hypertension
- Visceral Adiposity, Liver Fat, and Atherogenic Dyslipidemia
- Visceral Adiposity and Inflammation
- Abdominal Obesity and Alterations in Haemostasis—Thrombosis
- Physiological and Metabolic Characteristics of Visceral Adipocytes
- The Endocrine Function of Adipose Tissue: Implications of Visceral Obesity for Patients with Cardiometabolic Risk
- Free Fatty Acid Metabolism in Visceral Obesity
- Animal Models of Visceral Obesity
- Insulin Sensitivity and Visceral Adiposity: Effects of Rimonabant
- Physical Activity in the Management of Visceral Obesity and Related Cardiometabolic Risk
- Can We Change the Lifestyle of High-Risk Patients? Lessons from the Prevention of Diabetes Trials
- Can We Change the Body Fat Distribution Phenotype? Lessons from PPAR_Agonists
- Is There an Optimal Diet for the Management of Abdominal Obesity and Related Cardiometabolic Risk
- The EC System and Central Control of Energy Balance—The Hypothalamus
- The EC System and Central Control of Energy Balance: The Nucleus Accumbens
- The EC System and the HPA Axis
- The EC System and Gut–Brain Interactions Relevant to Satiety
- The Endogenous Cannabinoid System in the Gastrointestinal Tract
- The EC System in the Adipose Tissue and Endocrine Pancreas
- The EC System in the Immune System and the Inflammatory Response
- The Endocannabinoid System in the Liver
- The Endocannabinoid System and Cardiovascular Disease
- The Endocannabinoid System, Energy Expenditure, and Thermogenesis
- Effects of Dietary Fatty Acids on Endocannabinoid Signaling in the Brain and Peripheral Organs
- Endocannabinoid Overactivity and Abdominal Obesity
- CB1 Antagonism in the Management of Abdominal Obesity
- Abdominal Obesity and the Endocannabinoid System CB1 Blockade, Insulin Resistance, and Type 2 Diabetes
- Abdominal Obesity as a Therapeutic Target to Manage the Atherogenic Dyslipidemia and Related Metabolic Abnormalities
- CB1 Blockade and Hypertension
- Future Developments 1: CB1 Blockade for Weight Gain Subsequent to Smoking Cessation
- Future Developments 2: Cannabinoid CB1 Receptor Blockade in Weight Gain Subsequent to Psychiatric Disorder Treatment
Jean-Pierre Després and Vincenzo Di Marzo
Isabelle Lemieux and Jean-Pierre Després
Paul Poirier and Caroline Rhéaume
Marja-Riitta Taskinen, Martin Adiels, and Jan Borén
Ulf Smith
Irène Juhan-Vague and Marie-Christine Alessi
Alain Veilleux and André Tchernof
Max Lafontan
Asem Ali and Michael D. Jensen
Derek M. Huffman and Nir Barzilai
Joyce M. Richey, Morvarid Kabir, Orison O. Woolcott, Stella P. Kim, Lisa N. Harrison, Darko Stefanovski, Isabel Hsu, Dan Zheng, Maya Lottati, Cathryn Kolka, Viorica Ionut, Karyn Catalano, Jenny D. Chiu, and Richard N. Bergman
Peter M. Janiszewski and Robert Ross
Jaakko Tuomilehto and Jaana Lindström
Zubin Punthakee and Hertzel C. Gerstein
Benôit Lamarche and Caroline Richard
Vincenzo Di Marzo
Tim C. Kirkham
Daniela Cota
Richard Jones, Galina Burdyga, David G. Thompson, and Graham J. Dockray
Angelo A. Izzo
Isabel Matias
Tracy A. Sherwood and Thomas W. Klein
Ariane Mallat and Sophie Lotersztajn
Pál Pacher and George Kunos
Luigi Bellocchio, Cristina Cervino, Valentina Vicennati, Renato Pasquali, and Uberto Pagotto
Alvin Berger and Vincenzo Di Marzo
Vincenzo Di Marzo and Jean-Pierre Després
Luc F. Van Gaal
André J. Scheen
Jean-Pierre Després
Luis M. Ruilope
Jaimee L. Heffner and Robert M. Anthenelli
Ester Fride, Shimon Rabichev, and Nikolai Gobshtis
- Jean-Pierre Despres is Professor at the Division of Kinesiology of the Department of Social and Preventive Medicine at Université Laval, Québec, Canada. He received his Ph.D. in Exercise Physiology from Université Laval and then pursued a post-doctoral training at the Department of Medicine of the University of Toronto. Dr. Després is Director of Research at the Québec Heart Institute in Québec City and holds the position of Scientific Director of the International Chair on Cardiometabolic Risk, a multi-disciplinary academic organisation based at Université Laval.
Dr. Després has been the Editor for the International Journal of Obesity from 1992 to 2000, and he is currently a member of the editorial boards of several scientific journals He also serves on the board of numerous organisation and has been the recipient of many awards. Dr. Després has published more than 480 papers in peer-reviewed journals and has written 50 book chapters.
- Vincenzo Di Marzo is Research Director at the Istituto di Chimica Biomolecolare, Pozzuoli (Naples), Italy, and Adjunct Associate Professor at Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA. Dr. Di Marzo received his first degree in chemistry from the University of Naples “Federico II”, in Italy, and his Ph.D. in biochemistry from the Imperial College of Science. Technology & Medicine, London, UK.
Among his many achievements, Dr. Di Marzo was the principal investigator of a Human Frontier in Science Organization grant and past president of the International Cannabinoid Research Society, and founded the Endocannabinoid Research Group, in which several laboratories working on endocannabinoids in the Naples area converge. He has coauthored over 340 articles in peer-reviewed scientific journals. In 2007 he received the Mechoulam Award for “his outstanding contributions to cannabinoid research”.
